Week_3_ethics_Malone - harboring the genes for...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
harboring the genes for Panton-Valentine leucocidin. / Clin Microbioi. 2004;42; 2080-2084. 15. Said-Salim B, Mathema B, Braughton K, et al. Differential distribution and ex- pression of Panton-Valentine leucocidin among community-acquired methicillin- resistant Staphylococcus aureus strains. / Clin Microbioi. 2005;43;3373-3379. 16. Spellberg B, Powers JH, Brass EF, Miller LG, Edwards JE Jn Trends in an- timicrobial drug development: implica- tions for the future. Clin Infect Dis. 2004;38:1279-1286. 17. Infectious Disease Society of America (IDSA). Bad Bugs, No Drugs. As Antibiotic Discovery Stagnates. A Pub- lic Health Crisis Brews. Alexandria, Va: IDSA; 2004. 18. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. De- velopment of Daptomycin resistance in vivo in methicillin-resistant Staphylococ- cus aureus. J Clin Microbioi. 2005,43: 5285-5287 19. Vikram HR, Havill NL. Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus au- reus vertebral osteomyelitis associated with reduced susceptibility to dapto- mycin./ Qin Microbioi. 2005;43: 5384-5387 20. Mangili A, Bica 1, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus au- reus bacteremia. Clin Infect Dis. 2005; 40:1058-1060. 21. Peeters MJ, Sarria JC. Clinical char- acteristics of linezolid-resistant Staphylo- coccus aureus infections. Amf Med Sd. 2005;330:102-104. 22. Angell M. 77ie Truth About Drug Companies: How They Deceive Us and What to Do About It. New York, NY: Random House; 2004. 23. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus au- reus. Trends Microbioi. 2001 ;9: 486-493. 24. Horowitz JB, Moehring HB. How property rights and patents affect antibi- otic resistance. Health Econ. 2004;13: 575-583. 25. Levy SB. Antibiotic resistance: consequences of inaction. Clin Infect Dis. 2001;33(suppl 3):S124-S129. 26. Dowling HF. The pharmaceutical industry and the doctor. What of the fu- ture? N Engl f Med 1961;264:75-79. 27. Trouiller P, OUiaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug devel- opment for neglected diseases: a defi- cient market and a public-health policy failure. Lancet 2002;359:2188-2194. 28. Office of Legislative Policy and Analysis. Legislative updates. Available at: http://olpa.od.nih.gov/legislation/ 109/pendinglegislation/bioterror.asp. Accessed July 26, 2006. 29. Centers for Disease Control and Prevention. Get Smart: Know When Antibiotics Work. Available at: http:// www.cdc.gov/drugresistance/community. Accessed November 15, 2005. 30. Alliance for the Prudent Use of Antibiotics. Home page. Available at: http://www.tufts.edu/med/apua. Ac- cessed November 15, 2005. 31.
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 09/08/2010 for the course SCWK 242 at San Jose State University .

Page1 / 7

Week_3_ethics_Malone - harboring the genes for...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online